Cirrhosis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 42: Line 42:


====Zinc====
====Zinc====
Zinc deficiency is commonly observed in patients with [[cirrhosis]].  Zinc supplementation with 220 mg twice a day orally may improve dysugesia and also helps in stimulating appatite.  Zinc supplementation can also help resolve muscle cramps.
Zinc deficiency is commonly observed in patients with [[cirrhosis]].  Supplementation with 220 mg Zinc twice a day orally may improve [[dysugesia]] and also helps in stimulating appetite.  Zinc supplementation can also help resolve [[muscle cramps]].
Low dose Zn supplementation could prevent deterioration of clinical status of cirrhosis and prevent excess Cu accumulation in non-alcoholic cirrhotic patients. Zn supplementation produces metabolic effects and trends towards improvements in liverfunction, hepatic encephalopathy, and nutritional status<ref name="pmid22827782">{{cite journal |author=Somi MH, Rezaeifar P, Ostad Rahimi A, Moshrefi B |title=Effects of Low Dose Zinc Supplementation on Biochemical Markers in Non-alcoholic Cirrhosis: A Randomized Clinical Trial |journal=Arch Iran Med |volume=15 |issue=8 |pages=472–6 |year=2012 |month=August |pmid=22827782 |doi=012158/AIM.006 |url=}}</ref>.
Low dose Zn supplementation could prevent deterioration of clinical status of cirrhosis and prevent excess Cu accumulation in non-alcoholic cirrhotic patients. Zn supplementation produces metabolic effects and trends towards improvements in liver function, [[hepatic encephalopathy]], and nutritional status<ref name="pmid22827782">{{cite journal |author=Somi MH, Rezaeifar P, Ostad Rahimi A, Moshrefi B |title=Effects of Low Dose Zinc Supplementation on Biochemical Markers in Non-alcoholic Cirrhosis: A Randomized Clinical Trial |journal=Arch Iran Med |volume=15 |issue=8 |pages=472–6 |year=2012 |month=August |pmid=22827782 |doi=012158/AIM.006 |url=}}</ref>.


==Treatment of Underlying Causes==
==Treatment of Underlying Causes==

Revision as of 12:40, 7 September 2012

Cirrhosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cirrhosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Cirrhosis medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cirrhosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cirrhosis medical therapy

CDC on Cirrhosis medical therapy

Cirrhosis medical therapy in the news

Blogs on Cirrhosis medical therapy

Directions to Hospitals Treating Cirrhosis

Risk calculators and risk factors for Cirrhosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]

Overview

Medical Therapy

Treatment of cirrhosis is directed most of the times towards treatment of complications like ascites, esophageal varices, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis. But some chronic constitutional symptoms, which include pruritus, hypogonadism, osteoporosis and anorexia should be treated as well.

Alcohol should be avoided by all patients with cirrhosis. Improvement in liver function is noticed in most patients after abstinence from alcohol.

Pruritus

Pruritus is a common symptom in chronic liver disease. Endogenous opioids have been proposed as the culprits for causing pruritus. Less severe itching can be treated using antihistamines and ammonium lactate topical solution. Cholestyramine is the drug of choice for treating pruritus of chronic liver disease. Severe itching requires ultraviolet light therapy and or plasmapheresis.

Other drugs that can be used with varying results include: diphenhydramine, hydroxyzine, ursodeoxycholic acid, rifampin and naltrexone (opiate).

Hypogonadism

Males with cirrhosis sometimes complain of loss of libido due to hypogonadism. The possible treatment option for these patients is topical testosterone preparations, but there exists no studies to prove the efficacy of such preparations.

Osteoporosis

Cirrhosisis one of the major causes of osteoporosis[1]. Calcium and vitamin D supplementation is suggested for all the patients who are at risk for osteoporosis and also for patients who are on corticosteroids for autoimmune liver disease.

Pain management in Cirrhosis

Cirrhotic patients can develop pain from ascites (back pain and abdominal pain) and gynecomastia (mastalgia). Pain management in cirrhosis has a special consideration as many analgesic and anti-inflammatory drugs are metabolized by the liver and dosage regulations are required to prevent further liver damage and drug toxicity. Drug dosages should be titrated as per the level of hepatic function in the patient. Dosage changes are required in patients with cirrhosis when they have the following:

Non-selective NSAIDs should be avoided in patients with cirrhosis because of the following complications:

  • Increased bleeding from varices
  • Impaired renal function
  • Development of diuretic resistant ascites

As per a study in humans which involved 28 patients with cirrhosis and ascites celecoxib seemed to be a reasonable option for pain management and anti-inflammatory treatment. But further studies are needed to prove the potential advantage of celecoxib over other NSAIDs.

Opioids should be used cautiously in patients with cirrhosis because they are metabolized by the liver through oxidation and glucuronidation and in cirrhosis, because of the reduced liver blood flow, reduced protein binding and reduced hepatic enzyme capacity, these drugs accumulate and the patient is prone to develop opiate toxicity.

Nutrition

Anorexia is a common symptom in cirrhosis patients who have ascites because of the direct compression of the bowel by the ascitic fluid. Adequate calories and proteins should be added to the diet of the patient. Patients should consume a balanced diet and one multivitamin daily. Vitamin D and K supplementation is needed in patients with cholestasis.

Excessive proteins in the diet places the patient at risk for hepatic encephalopathy. Low protein diet causes muscle wasting. Therefore diet should be adequately titrated. Branched-chain amino acids (BCAA) can function as pharmacologic nutrients for patients with decompensated cirrhosis.

Zinc

Zinc deficiency is commonly observed in patients with cirrhosis. Supplementation with 220 mg Zinc twice a day orally may improve dysugesia and also helps in stimulating appetite. Zinc supplementation can also help resolve muscle cramps. Low dose Zn supplementation could prevent deterioration of clinical status of cirrhosis and prevent excess Cu accumulation in non-alcoholic cirrhotic patients. Zn supplementation produces metabolic effects and trends towards improvements in liver function, hepatic encephalopathy, and nutritional status[2].

Treatment of Underlying Causes

Alcoholic Liver Disease Medical Therapy
Hepatitis C Medical Therapy
Hepatitis B Medical Therapy
Autoimmune Hepatitis Medical Therapy
Primary Biliary Cirrhosis Medical Therapy
Primary Sclerosing Cholangitis Medical Therapy
Wilson's Disease Medical Therapy

Treatment of Complications

Ascites

Treatment of Ascites

Salt restriction is often necessary, as cirrhosis leads to accumulation of salt (sodium retention). Diuretics may be necessary to suppress ascites.

Esophageal Variceal Bleeding

Esophageal Varices Treatment

For portal hypertension, propranolol is a commonly used agent to lower blood pressure over the portal system. In severe complications from portal hypertension, transjugular intrahepatic portosystemic shunting is occasionally indicated to relieve pressure on the portal vein. As this can worsen encephalopathy, it is reserved for those at low risk of encephalopathy, and is generally regarded only as a bridge to liver transplantation or as a palliative measure.

Hepatic Encephalopathy

Hepatic Encephalopathy Treatment

High-protein food increases the nitrogen balance, and would theoretically increase encephalopathy; in the past, this was therefore eliminated as much as possible from the diet. Recent studies show that this assumption was incorrect, and high-protein foods are even encouraged to maintain adequate nutrition.

Hepatorenal Syndrome

Hepatorenal Syndrome Treatment

The hepatorenal syndrome is defined as a urine sodium less than 10 mmol/L and a serum creatinine > 1.5 mg/dl (or 24 hourcreatinine clearance less than 40 ml/min) after a trial of volume expansion without diuretics.[3]

Spontaneous Bacterial Peritonitis

Spontaneous Bacterial Peritonitis Medical Therapy

Cirrhotic patients with ascites are at risk of spontaneous bacterial peritonitis.

References

  1. Giouleme OI, Vyzantiadis TA, Nikolaidis NL; et al. (2006). "Pathogenesis of osteoporosis in liver cirrhosis". Hepatogastroenterology. 53 (72): 938–43. PMID 17153457.
  2. Somi MH, Rezaeifar P, Ostad Rahimi A, Moshrefi B (2012). "Effects of Low Dose Zinc Supplementation on Biochemical Markers in Non-alcoholic Cirrhosis: A Randomized Clinical Trial". Arch Iran Med. 15 (8): 472–6. doi:012158/AIM.006 Check |doi= value (help). PMID 22827782. Unknown parameter |month= ignored (help)
  3. Ginés P, Arroyo V, Quintero E; et al. (1987). "Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study". Gastroenterology. 93 (2): 234–41. PMID 3297907.

Template:WH Template:WS